Bone marrow-derived cells and epithelial tumours: More than just an inflammatory relationship

Current Opinion in Oncology

Volumn 21, Issue 1, 2009, Pages 77-82

  Alison, Malcolm R ^a,d   Lim, Susan ^b   Houghton, Jean Marie ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d ICMS   (United Kingdom)

Author keywords

Bone marrow cells; Metastasis; Myeloid derived suppressor cells; Myofibroblasts; Niche cells

Indexed keywords

BEVACIZUMAB; CHEMOKINE; DOXYCYCLINE; GROWTH FACTOR; INTEGRIN; MATRIX METALLOPROTEINASE;

BONE MARROW; BONE MARROW CELL; CANCER GROWTH; CANCER INVASION; ENZYME RELEASE; EPITHELIUM TUMOR; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATORY CELL; MESENCHYMAL STEM CELL; METASTASIS; MYOFIBROBLAST; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PARACRINE SIGNALING; PLANT GROWTH; PRIORITY JOURNAL; REVIEW; STEM CELL; STROMA CELL; T LYMPHOCYTE;

ANIMALS; BONE MARROW CELLS; BONE MARROW NEOPLASMS; HUMANS; INFLAMMATION; NEOPLASMS, GLANDULAR AND EPITHELIAL;

EID: 58149264944     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32831de4cf     Document Type: Review

References (46)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-867.
2. Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431:461-466.
3. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118.285-296.
4. Direkze NC, Jeffrey R, Hodivala-Dilke K, et al. Bone marrow-derived stromal cells express lineage-related messenger RNA species. Cancer Res 2006; 66:1265-1269.
5. Houghton J, Stoicov C, Nomura S, et al. Gastric cancer originating from bone marrow-derived cells. Science 2004; 306:1568-1571.
6. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6:392-401.
7. Li H, Fan X, Houghton J. Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem 2007; 101:805-815.
8. Quan TE, Cowper SE, Bucala R. The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep 2006; 8:145-150.
9. LaRue AC, Masuya M, Ebihara Y, et al. Hematopoietic origins of fibroblasts: I. In vivo studies of fibroblasts associated with solid tumors. Exp Hematol 2006; 34:208-218.
10. Sangai T, Ishii G, Kodama K, et al. Effect of differences in cancer cells and tumor growth sites on recruiting bone marrow-derived endothelial cells and myofibroblasts in cancer-induced stroma. Int J Cancer 2005; 115:885-892.
11. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within • tumour stroma promote breast cancer metastasis. Nature 2007; 449:557-563. Elucidates the paracrine relationship between human bone marrow-derived MSCs and breast carcinoma cells that enhances tumour motility and metastasis.
12. Hall B, Dembinski J, Sasser AK, et al. Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles. Int J Hematol 2007;86:8-16.
13. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1 -positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 2005; 438:820-827.
14. Kitamura T, Kometani K, Hashida H, et al. SMAD4-deficient intestinal tumors • recruit CCR1+ myeloid cells that promote invasion. Nat Genet 2007; 39:467-475. Highlights the significance of the loss of TGFβ signalling in murine colonic cancer for the up-regulation of the chemoattractant CCL9, promoting ingress of MMP- producing cap cells.
15. Dolcetti L, Marigo I, Mantelli B, et al. Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett 2008; 267:216-225.
16. Yang L, DeBusk LM, Fukuda K, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004; 6:409-421.
17. Yang L, Huang J, Ren X, et al. Abrogation of TGF beta signaling in mammary •• carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008; 13:23-35. Demonstrated that loss of the type II TGFβ receptor in mammary carcinoma recruits MDSCs through increased chemokine production. In turn MDSCs produce MMPs and TGFβ, which cause immune suppression, turning TGFβ from a tumour suppressor to a tumour promoter.
18. Nagaraj S, Gupta K, Pisarev V, et al. Altered recognition of antigen is a • mechanism of CD8+T cell tolerance in cancer. Nat Med 2007; 13:828-835. Demonstrated a central role for MDSCs in inducing antigen-specific CD8+ T-cell tolerance, a major mechanism of tumour escape.
19. Kujawski M, Kortylewski M, Lee H, et al. Stat3 mediates myeloid cell- • dependent tumor angiogenesis in mice. J Clin Invest 2008 [Epub ahead of print]. Describes a central role for STAT-3 mediated cell signalling not just in tumour cells, but also in MDSCs, macrophages and endothelial cells in the tumour vicinity.
20. + cells facilitated vasculogenesis, although the source of the new endothelial cells was unclear.
21. Hämmerling GJ, Ganss R. Vascular integration of endothelial progenitors during multistep tumor progression. Cell Cycle 2006; 5:509-511.
22. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7:1194-1201.
23. Gao D, Nolan DJ, Mellick AS, et al. Endothelial progenitor cells control the •• angiogenic switch in mouse lung metastasis. Science 2008; 319:195-198. Using mouse models of lung and breast cancer, established the importance of bone marrow-derived EPCs for the angiogenic switch (the ability of micrometastases to grow further by virtue of inducing new blood vessel growth). When the transcription factor Id1 was suppressed after micrometastasis formation, there was no EPC recruitment from the bone marrow, neovascularization of the micrometastases did not occur, macrometastasis formation was decreased and the tumour-bearing mice survived longer.
24. Purhonen S, Palm J, Rossi D, et al. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci U S A 2008; 105:6620-6625.
25. Kerbel RS, Benezra R, Lyden DC, et al. Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas. Proc Natl Acad Sci U S A 2008; 105:E54. [author reply E55].
26. Du R, Lu KV, Petritsch C, et al. HIF1 alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008; 13:206-220.
27. Peters BA, Diaz LA, Polyak K, et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 2005; 11:261-262.
28. Dome B, Timar J, Dobos J, et al. Identification and clinical significance of circulating endothelial progenitor cells in human nonsmall cell lung cancer. Cancer Res 2006; 66:7341-7347.
29. Ho JW, Pang RW, Lau C, et al. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma Hepatology 2006; 44:836-843.
30. Lin EH, Hassan M, Li Y, et al. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer 2007; 110:534-542.
31. Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003; 63:4342-4346.
32. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF- specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145-147.
33. Shaked Y, Bocci G, Munoz R, et al. Cellular and molecular surrogate markers to monitor targeted and nontargeted antiangiogenic drug activity and determine optimal biologic dose. Curr Cancer Drug Targets 2005; 5:551-559.
34. Naik RP, Jin D, Chuang E, et al. Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. Breast Cancer Res Treat 2008; 107:133-138.
35. Alison MR, Lovell MJ, Direkze NC, et al. Stem cell plasticity and tumour formation. Eur J Cancer 2006; 42:1247-1256.
36. Houghton J, Wang TC. Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. Gastroenterology 2005; 128:1567-1578.
37. Li H, Fan X, Kovi RC, et al. Spontaneous expression of embryonic factors and p53 point mutations in aged mesenchymal stem cells; a model of age-related tumorigenesis in mice. Cancer Res 2007; 67:10889-10898.
38. Liu C, Chen Z, Chen Z, et al. Multiple tumor types may originate from bone marrow-derived cells. Neoplasia 2006; 8:716-724.
39. Arai Y, Arai H, Aoyagi A, et al. A solid tumor of donor cell origin after allogeneic peripheral blood stem cell transplantation. Am J Transpl 2006; 6:3042-3043.
40. Aractingi S, Kanitakis J, Euvrard S, et al. Skin carcinoma arising from donor cells in a kidney transplant recipient. Cancer Res 2005; 65:1755-1760.
41. Barozzi P, Luppi M, Facchetti F, et al. Posttransplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med 2003; 9:554-561.
42. Morath C, Rohmeiss P, Schwenger V, et al. Transmission of donor derived small cell carcinoma cells by a nontumor bearing allograft. Transplantation 2005;80:540-541.
43. Golfinopouloss V, Pentheroudakis G, Kamakari S, et al. Donor derived breast cancer in a bone marrow transplantation recipient. Breast Cancer Res Treat 2008. [Epub ahead of print]
44. Avital I, Moreira AL, Klimstra DS, et al. Donor derived human bone marrow cells contribute to solid organ cancers developing after bone marrow transplantation. Stem Cells 2007; 25:2903-2909.
45. Cogle CR, Theise ND, Fu DT, et al. Bone marrow contributes to epithelial cancers in mice and humans as developmental mimicry. Stem Cells 2007; 25:1881-1887.
46. Pawelek JM, Chakraborty AK. Fusion of tumour cells with bone marrowderived cells: a unifying explanation for metastasis. Nat Rev Cancer 2008; 8:377-386.